Google
LLY 株価分析 — ELI LILLY AND COMPANY (Healthcare >> Drug Manufacturers - General)
LLY に関するよくある質問
LLYのPER（株価収益率）は？
ELI LILLY AND COMPANY（LLY）は現在PER 40.75倍で取引されています。
LLYのROE（自己資本利益率）は？
ELI LILLY AND COMPANYのROEは81.01%です。
LLYの配当利回りは？
ELI LILLY AND COMPANYの配当利回りは0.51%です。
LLYの品質スコア（Quality Score）は？
当社のAIはLLYの総合財務品質を100点中92点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
LLYは今が買い時ですか？
当社AIのタイミングスコアは100点中67点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
LLYはどのセクターに属しますか？
ELI LILLY AND COMPANYはHealthcare >> Drug Manufacturers - Generalセクターに分類されます（NYSE市場）
LLY AI Analysis Summary
Our AI summary for LLY: ELI LILLY AND COMPANY (NYSE), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at a P/E of 40.75, ROE of 81.01%, a dividend yield of 0.51%. Its financial Quality Score stands at 92/100 — fundamentals stronger than most of the market. The AI Timing Score is 67/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1,148.84
Price
-6.13
(-0.53%)
Day Change
|
|
|---|
LLY, ファンダメンタルスコアはexcellent ( ファンダメンタル = 92) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
ROAがROEに比べて低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are ok , financial health is not quite good , and ability to make profit is very good , ...
| Deepscope 分析 |
|
60% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 1.04 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
1189
|
| Magic Formula Rank by ROE |
1189
|
| Magic Formula Rank by ROIC |
1291
|
| Price | 1,148.84 |
| PBV / Sector |
33.01 / 2.68
|
| Earning Per Share | 28.19 |
| PE / Sector |
40.75 / 27.65
|
| PEG or PE/Growth / Sector |
0.66 / 0.28
|
| Average 1M Daily Value |
2,374.95 M
GREAT
|
| Average 1W Daily Value |
2,727.95 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
52% |
| ポイントになる統計 |
|
81% |
| 配当 |
|
8% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:07 |
| Symbol | LLY |
| Name | ELI LILLY AND COMPANY |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NYSE |
| Listed Shares | 891.74 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,029,934.48 / 256,404.20 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Lilly Corporate Center, Indianapolis, IN, United States, 46285
Phone: 317 276 2000
Website: https://www.lilly.com
Employees: 50,000
Description: Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
